Clinical Trial Update: Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis)) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy for erythema migr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease

Drugs mentioned

• Saccharomyces boulardii CNCM I-745 (Saccharomyces boulardii)

Snippet

Sponsor: Biocodex | Conditions: Erythema Migrans of Lyme Disease | Phase 4 | Status: RECRUITING